Johnson & Johnson (NYSE:JNJ) Shares Purchased by Howard Financial Services LTD.

Howard Financial Services LTD. boosted its position in Johnson & Johnson (NYSE:JNJ) by 11.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,685 shares of the company’s stock after purchasing an additional 365 shares during the period. Howard Financial Services LTD.’s holdings in Johnson & Johnson were worth $597,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Bellevue Group AG raised its stake in Johnson & Johnson by 23.9% during the 4th quarter. Bellevue Group AG now owns 28,280 shares of the company’s stock valued at $4,433,000 after purchasing an additional 5,457 shares during the period. Icon Wealth Advisors LLC acquired a new position in shares of Johnson & Johnson in the fourth quarter worth $1,392,000. Putnam Investments LLC increased its stake in shares of Johnson & Johnson by 0.3% in the fourth quarter. Putnam Investments LLC now owns 624,978 shares of the company’s stock worth $97,959,000 after acquiring an additional 2,128 shares during the last quarter. Caxton Associates LP increased its stake in shares of Johnson & Johnson by 199.4% in the fourth quarter. Caxton Associates LP now owns 18,341 shares of the company’s stock worth $2,875,000 after acquiring an additional 12,216 shares during the last quarter. Finally, First Financial Bankshares Inc acquired a new position in shares of Johnson & Johnson in the fourth quarter worth $78,509,000. Institutional investors own 69.55% of the company’s stock.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on JNJ. Daiwa Capital Markets downgraded shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $160.00 to $150.00 in a research note on Tuesday, July 23rd. TD Cowen dropped their price target on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, July 18th. Royal Bank of Canada upped their price target on shares of Johnson & Johnson from $175.00 to $178.00 and gave the stock an “outperform” rating in a research note on Tuesday. Morgan Stanley upped their price objective on shares of Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a report on Thursday, July 18th. Finally, StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $173.43.

Johnson & Johnson Stock Up 0.1 %

JNJ stock opened at $159.81 on Wednesday. The business’s 50-day simple moving average is $162.59 and its 200 day simple moving average is $154.36. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The company has a market cap of $384.61 billion, a PE ratio of 9.95, a price-to-earnings-growth ratio of 2.69 and a beta of 0.52. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping the consensus estimate of $2.71 by $0.11. The firm had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. Johnson & Johnson’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same period last year, the business earned $2.80 earnings per share. On average, research analysts anticipate that Johnson & Johnson will post 10.02 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were paid a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 annualized dividend and a yield of 3.10%. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.